45 results about "Hb vaccine" patented technology

The invention relates to a phosphothioate oligodeoxynucleotide with immunostimulation activity. A 5'-NTCGTT-3' primitive with two or more than two copies is arranged in the sequence thereof and the length thereof is of 15 to 35 nucleotide; wherein, CpG is unmethylated; and N does not represent A or G. The phosphothioate oligodeoxynucleotide has excellent immunostimulation activity both to a human body and a mouse immunocyte in vitro; and the immunostimulation activity in the human body thereof can be estimated according to the results of immunostimulation activity to the mouse. As a vaccine adjuvant, the phosphothioate oligodeoxynucleotide can remarkably enhance the immune response of the mouse to the hepatitis B vaccine of gene engineering, and can lead the immune response to lean to the direction of TH1, thus can be used for controlling and curing hypersusceptibility and infection. Meanwhile, the phosphothioate oligodeoxynucleotide of the invention also has excellent activity to inhibit the growth of tumors in the body of the mouse.

The invention provides a bispecific antibody A3B5-BsAb for a hepatitis B surface protein. The bispecific antibody is formed by combining an antibody A3D5 with an antibody B5H6. The bispecific antibody has better HBV virus neutralization ability and HBsAg release inhibition ability than single use of the antibody A3D5 and the antibody B5H6, and has strong synergistic effects, so the bispecific antibody is likely to prevent HBV infection related hepatitis, hepatic cirrhosis and liver cancer. The bispecific antibody is a completely humanized antibody obtained through cloning HBsAg specific memory B cells in the peripheral blood of hepatitis B vaccine inoculated volunteer, has lower immunogenicity than murine, chimeric and humanized antibodies, and can be used to prepare hepatitis B virus related hepatopathy prevention or treatment drugs or diagnose reagents.

The present invention involves a new viral immunotherapy drug complex, and in particular, a viral immunotherapy drug complex for persistent hepatitis B infection. The present drug consists of antiviral drugs, immunoregulating drugs and a recombinant hepatitis B vaccine, for use in treating hepatitis B and in particular chronic hepatitis B infections. Antiviral drugs of the described drug complex are selected among α-IFN and nucleosides; the immunoregulating drugs are selected from among GM-CSF and similar.

The invention discloses HBV pre-c-Fc recombinant protein and a coding nucleotide sequence thereof and discloses a recombinant vector containing a coding sequence of the protein and a host cell. The invention further discloses a recombinant baculovirus, a method of obtaining the recombinant baculovirus, and a method of expressing the HBV pre-c-Fc recombinant protein in an insect baculovirus expression system, and also discloses a recombinant baculovirus containing a HBV pre-c-Fc coding gene and applications of the HBV pre-c-Fc recombinant protein in preparation of vaccines or medicines preventing or treating hepatitis B. After a BALB/c mouse is subjected to injection immunization with the HBV pre-c-Fc recombinant protein, detection shows that the generating amount of a hepatitis B virus core protein antibody in serum of the mouse is far higher than that in a situation that an antigen used for preparing hepatitis B vaccines in traditional methods is used.

The invention relates to sulpho-oligodeoxynucleotide with immunostimulation activities. The sequence of the sulpho-oligodeoxynucleotide has two or more than two copied 5'-NTCGTT-3' elements having 15 to 35 nucleotides respectively, wherein CpG is non-methylated and N does not represent A or G. In vitro, the sulpho-oligodeoxynucleotide has high immunostimulation activities for the immunocytes of human and a mouse, and the immunostimulation activities of the sulpho-oligodeoxynucleotide in a human body can be evaluated according to the result of the immunostimulation activities in mouse. Used asa vaccine adjuvant, the sulpho-oligodeoxynucleotide can obviously strengthen the immune response of the mouse to a genetic engineering hepatitis B vaccine and make the immune response deflected to a TH1 direction, and thus, it is proved that the sulpho-oligodeoxynucleotide can be used for preventing and treating allergy and infection. Meanwhile, the sulpho-oligodeoxynucleotide has high tumor growth restraining activities in the mouse body.

The invention discloses a hepatitis B vaccine, and in particular discloses a hepatitis B vaccine which contains an immunopotentiator and can induce an organism to generate specific immunity in a state of chronic hepatitis B virus infection. The hepatitis B vaccine disclosed by the invention contains a Toll-like receptor agonist serving as the immunopotentiator.

The invention provides a completely humanized monoclonal antibody B5H6 aiming at hepatitis B virus (HBV) surface protein and a gene for encoding the antibody. An experiment shows that the antibody B5H6 can be specifically combined with HBsAg protein, has relatively good HBV neutralization activity and then can resist the progresses of HBV infection related hepatitis, liver cirrhosis and liver cancers. Meanwhile, because the antibody is a completely humanized monoclonal antibody cloned from memory B cells with specific HBsAg in peripheral blood of a volunteer vaccinated with a hepatitis B vaccine, the antibody has immunogenicity lower than that of murine, chimeric and humanized antibodies, and can be used for preparing medicaments or diagnostic reagents for preventing or treating hepatitis B virus related hepatic diseases.

The invention provides an anti-hepatitis B virus surface antigen completely humanized human antibody A3D5 and a gene for encoding the antibody. Experiments show that the antibody A3D5 can specifically bind to an HBsAg protein, and has good HBV neutralization activity in order to possibly prevent HBV infection related hepatitis, hepatic cirrhosis and liver cancer. The antibody is a completely humanized human antibody obtained through cloning HBsAg specific memory B cells in the peripheral blood of hepatitis B vaccine inoculated volunteer, has lower immunogenicity than murine, chimeric and humanized antibodies, and can be used to prepare hepatitis B virus related hepatopathy prevention or treatment drugs or diagnose reagents.

The invention provides an analytical method of a hepatitis B vaccine. The analytical method comprises the following steps: (a) repeatedly freezing and thawing a hepatitis B vaccine sample at-15 DEG Cor below for at least one time, (b) mixing the freeze-thawed hepatitis B vaccine sample with hydrochloric acid in a volume ratio of 1: (1-2), and incubating at 37 DEG C for 1-3 hours, and (c) finally,adding a protective agent Triton100, and carrying out water bath for 1-3 hours at 37 DEG C to finish analysis. According to the present invention, the effective components in the hepatitis B vaccinecan be effectively separated from the adjuvant, such that the effective components can be accurately monitored through the immunoassay kit. Due to the fact that the analysis rate of previous analysisliquid is low, an existing method for determining the activity of the hepatitis B vaccine is an animal method, animal experiments can be effectively replaced after a new analysis mode is invented, andanimal cost is saved.

The invention discloses a gene VII type Newcastle disease marker vaccine strain as well as a preparation method and application thereof. A reverse genetic manipulation technology is utilized, a wholegenome transcription plasmid of a serum type 2 avian paramyxovirus Y2 strain is used as a skeleton, extracellular domains of F and HN genes of the serum type 2 avian paramyxovirus Y2 strain are respectively replaced with extracellular domains of F and HN genes of a gene VII Newcastle disease virus strain, and a recombinant chimeric virus is obtained through virus rescue. The vaccine strain is preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: 202052. The chimeric virus can be used for prevention and control of the main epidemic gene VII Newcastle disease in China. Meanwhile, the chimeric virus does not contain a Newcastle disease virus NP protein, and virus aiming at a Newcastle disease antibody NP protein cannot be generated after chickens are immunized. The rY2-HB vaccine strain immunized chicken flocks are subjected to antibody detection by a conventional Newcastle disease virus NP antibody ELISA detection method, NP antibody generated by clinical wild strains can be specifically detected, vaccine interference generated by antibody strains is eliminated, and monitoring and purification of Newcastle disease are facilitated.

A hepatitis B vaccine comprising a surface antigen particle that has only hepatitis B virus L protein or a variant thereof assembling on a lipid membrane to form the particle.

The invention belongs to the field of biotechnology, and particularly relates to an immunologic adjuvant and a preparation method thereof. The invention provides a synergistic effect of innate immune synergizing molecular 3'-deoxyadenosine or a mixture of 3'-deoxyadenosine and MHC epitope peptide or covalent conjugates on vaccines and antigens. The immunologic adjuvant can effectively enhance the immune effect of various vaccines (antigens), such as rabies vaccines, Hepatitis B vaccines, tuberculosis vaccines, various antigens and the like, obviously increase the titer of protective antibodies in animal bodies and the number and the functions of immune effector cells, and simultaneously accelerate the formation of the antibodies and cells obviously. The preparation method for the immunologic adjuvant is easy to implement, and can be used for developing high-efficient and quick synergistic vaccines. Therefore, the preparation method has excellent application prospect, and will bring huge social effect and economic benefits.

This invention relates to a HB vaccine enhancing protein, its gene, gene engineering method for expressing this protein, and the application of this method. The cDNA of this protein, which is screened out from human liver cDNA library, is sequenced and then cloned into prokaryotic or eukaryotic (animal or plant) cell for expression of protein coded by the cDNA (for example, cloning into prokaryotic expression carrier and expression in E. coli) and purification of the protein. The protein obtained, when used with HB vaccine, can significantly increase the effect of the vaccine, the immune power of HBV carrier, and the titer of antibody. The protein can be used as an adjutant to HB vaccine.

The present invention relates to a transnasal administration system which can be used for the prevention and treatment of hepatitis B and is combined with a medical nozzle device for use in the administration of a hepatitis B vaccine composition to the nasal cavity mucosa, wherein the hepatitis B vaccine composition is intended to be administered with a trans-nasal-mucosa spray.

The invention provides application of polyinosinic acid in preparation of a biological agent for improving the response level of HBsAg positive mother infant hepatitis B vaccines, and belongs to the technical field of biological agents. The invention discloses application of polyinosinic acid in preparation of a biological agent for improving the response level of HBsAg positive mother infant hepatitis B vaccines. HBeAg of an HBsAg positive mother inhibits a TLR3 signal channel, and placenta immunity is influenced to reduce the immune level of an infant, so that no/weak response of a hepatitis B vaccine is caused. The polyinosinic acid activates a trophoblast cell TLR3 signal channel to increase secretion of IL-2, increase the proportion of CD4 + T cells in PBMC, reduce the proportion of Treg cells and improve the immune level of the body, and rHBsAg stimulation can improve the expression quantity of IL-6 and the proportion of myelodendritic cells (mDC), reduce the expression of IL-10 and improve the anti-HBs level.Therefore, therefore the polyinosinic acid is beneficial to improving the response level of the body to the hepatitis B vaccines.